Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy

NCT05028634 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting

Interventions

BIOLOGICAL: Tetanus, diphtheria, and acellular pertussis vaccine
BIOLOGICAL: Pneumococcal polysaccharide vaccine
BIOLOGICAL: Seasonal influenza vaccine

Sponsor

Celgene